TiumBio Co Ltd Ordinary Shares 321550
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 321550 is a good fit for your portfolio.
News
-
TiumBio Announces Positive Topline Data from Phase 2a Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain
-
TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients
-
TiumBio to Initiate Phase 2 Trial of TU2218 for Cancer
Trading Information
- Previous Close Price
- —
- Day Range
- KRW 6,700.00–6,880.00
- 52-Week Range
- —–—
- Bid/Ask
- KRW 6,870.00 / KRW 6,880.00
- Market Cap
- KRW 171.65 Bil
- Volume/Avg
- 67,702 / 147,900
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 34.20
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
TiumBio Co Ltd is a Biopharmaceutical company. It is engaged in research and development of rare and intractable diseases. The company's products are in pipeline. It offers products such as Idiopathic pulmonary fibrosis therapies, immune chemotherapy, endometriosis therapies, hemophilia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 53
- Website
- http://www.tiumbio.com
Comparables
Valuation
|
Metric
|
321550
|
115450
|
226950
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.71 | 3.63 | 7.32 |
Price/Sales | 34.20 | 11.23 | 13.02 |
Price/Cash Flow | — | 452.21 | — |
Price/Earnings
321550
115450
226950
Financial Strength
|
Metric
|
321550
|
115450
|
226950
|
|---|---|---|---|
Quick Ratio | — | 1.18 | 4.82 |
Current Ratio | 4.52 | 1.64 | 5.80 |
Interest Coverage | −7.20 | −6.88 | −4.92 |
Quick Ratio
321550
115450
226950
Profitability
|
Metric
|
321550
|
115450
|
226950
|
|---|---|---|---|
Return on Assets (Normalized) | −15.28% | −1.84% | −18.88% |
Return on Equity (Normalized) | −34.91% | −2.38% | −52.41% |
Return on Invested Capital (Normalized) | −17.65% | −2.42% | −20.04% |
Return on Assets
321550
115450
226950
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Trcpqwtyhz | Vvgpw | $595.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vkbwqdv | Yysbrpn | $117.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tyyyvgg | Cppfr | $108.5 Bil | |
MRNA
| Moderna Inc | Jlsqdycq | Jlq | $63.9 Bil | |
BNTX
| BioNTech SE ADR | Cbscfrlg | Jqdj | $23.4 Bil | |
ARGX
| argenx SE ADR | Nwxpcch | Pqxd | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wchnynqb | Npdsq | $18.7 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Txhtcwqc | Ndgkmy | $14.3 Bil | |
INCY
| Incyte Corp | Fpqhccyg | Bvzrdn | $12.9 Bil | |
UTHR
| United Therapeutics Corp | Qvdgzrz | Vvm | $12.1 Bil |